We're working on something new at CrunchBase. Edits have been disabled for a few days, but you can still contact us for urgent changes.
Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Degrees

University of California, Berkeley, BA
Molecular Biology
University of California, Berkeley, BS
chemistry
Massachusetts Institute of Technology (MIT), PhD
biology

Current Companies

Board of Directors
Principal
Principal, ProQuest Investments
Board of Directors
Board Observer
Board of Directors
Board of Directors

Former Companies

Associate

Former Financial Organizations

Web Presences

Tags

Karen Hong

Dr. Hong joined ProQuest in 2001 as an Associate and became a Principal in 2004. Prior to joining ProQuest, Dr. Hong provided technical consultation to the healthcare group at BancBoston Ventures and pursued academic research in molecular biology and chemistry. Most recently, she led numerous research projects in the area of mammalian cancer genetics and genomics in the laboratory of Dr. Eric Lander at the Whitehead Institute for Biomedical Research.

Currently, Dr. Hong serves on the Board of Directors of Agile Therapeutics and represents ProQuest as an observer on the Board of Directors of Predictive Biosciences. In addition, she worked closely with ProQuest portfolio companies Gloucester Pharmaceuticals (acquired by Celgene) and BioRexis Pharmaceutical Corp. (acquired by Pfizer) among others.

Dr. Hong received a B.S. in chemistry and a B.A. in molecular biology from the University of California at Berkeley, where she graduated with honors and as a member of Phi Beta Kappa. She received a Ph.D. in biology from the Massachusetts Institute of Technology.

Recent Milestones

Videos

Sources

Edit This Page
Last Edited 10/27/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy